Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Infections | Internal Medicine | Pediatrics | Conference News

Back to Journal Articles

IAVC: Vaccine Offers Modest Malaria Protection to Infants

Last Updated: November 09, 2012.

 

One month after third RTS,S/AS01 dose, 99.7 percent positive for anti-circumsporozoite antibodies

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For infants, vaccination with the RTS,S/AS01 vaccine, coadministered with Expanded Program on Immunization vaccines, is associated with modest protection against clinical and severe malaria, according to a study published online Nov. 9 in the New England Journal of Medicine to coincide with presentation at the International African Vaccinology Conference, held from Nov. 8 to 11 in Cape Town, South Africa.

FRIDAY, Nov. 9 (HealthDay News) -- For infants, vaccination with the RTS,S/AS01 vaccine, coadministered with Expanded Program on Immunization (EPI) vaccines, is associated with modest protection against clinical and severe malaria, according to a study published online Nov. 9 in the New England Journal of Medicine to coincide with presentation at the International African Vaccinology Conference, held from Nov. 8 to 11 in Cape Town, South Africa.

Salim Abdulla, M.D., Ph.D., and colleagues from the RTS,S Clinical Trials Partnership, examined the outcomes of 6,537 infants, aged 6 to 12 weeks, from a phase 3 trial of RTS,S/AS01 for malaria. RTS,S/AS01 or a comparator vaccine was administered in conjunction with Expanded Program on Immunization (EPI) vaccines in a three-dose monthly schedule.

During the 14 months after the first dose of vaccine, the researchers found that the incidence of the first or only episode of clinical malaria was 0.31 per person-year in the RTS,S/AS01 group and 0.40 per person-year in the control group, for a vaccine efficacy of 30.1 percent in the intention-to-treat population. In the per-protocol population, vaccine efficacy was 31.3 percent. In the intention-to-treat and per-protocol populations the vaccine efficacy against severe malaria was 26.0 and 36.6 percent, respectively. The frequency of serious adverse events was similar between the groups. One month following administration of the third dose of RTS,S/AS01, 99.7 percent of those vaccinated were positive for anti-circumsporozoite antibodies.

"The RTS,S/AS01 vaccine coadministered with EPI vaccines provided modest protection against both clinical and severe malaria in young infants," the authors write.

The study was partially funded by GlaxoSmithKline, to which several authors disclosed financial ties.

Abstract
Full Text
Editorial
More Information

Copyright © 2012 HealthDay. All rights reserved.


Previous: Newly ID'd Gene Important in Hemoglobin Synthesis Next: Pregnancy Risks Up for Women With Bipolar Disorder

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.